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Levosimendan in acute 
heart failure
ABSTRACT
Numerous adverse effects and an increased mortality are the reasons why many clinicians are often unsuccessful with the 
inotropic agents presently in use.  New therapeutic agents have been developed in the last few years to assist the clinician 
in the stabilization, support and treatment of cardiovascular disease.
One of the newest groups of inotropic agents is a group of agents, which increase the affinity of myofibrils for calcium and 
are called calcium sensitizers. Calcium sensitizers are the newest heterogeneous group of inotropic agents. The best known 
representatives of this group are levosimendan and pimobendan. Positive inotropic effects of levosimendan are achieved 
by its binding to troponin C and calcium, thereby stabilizing the tropomyosin molecule and prolonging the duration of actin-
myosin overlap without a change in the net concentration of intracellular calcium. The vasodilatory effect of levosimendan is 
reached through activation of ATP-dependent potassium channels. This leads to a decrease in both afterload and preload, 
increased coronary blood flow and a resultant anti-ischemic effect. Levosimendan is therefore categorized as an anti-
ischemic inotropic agent. Furthermore, experiments have confirmed that levosimendan as an opener of KATP – channels 
in the mitochondria and the sarcolemma of myocites may have an effect on the myocardium preconditioning.
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In 1908, Sir James McKenzie first 
described “low cardiac output syn-
drome”. Clinically, this syndrome 
results in global hypoperfusion, whose 
treatment requires inotropic support by 
vasoactive medications, or mechanical 
intervention to support and improve 
cardiac work. In the early 1900s′ the 
mainstay of cardiac treatment was digi-
talis with the addition of a salt reduced 
diet. Accumulated fluids within pleural 
and peritoneal spaces were eliminated 
by mechanical means or by drainage. 
The use of diuretics was instituted dur-
ing the 1920’s. The treatment of con-
gestive heart failure entered a second 
phase in the 1950’s, when vasodilators 
were introduced into the physicians’ 
therapeutic armamentarium. With the 
introduction of the inotropic agents in 
1980s’, a third great period in the thera-
py of heart failure had begun.
The catecholamine inotropic agents 
were among the earliest vasoactive 
agents and remain important and useful 
today although there can be some neg-
ative consequences of their use (table 
1). A major side effect is an increase in 
myocardial oxygen consumption. (1)
A lack of tachyphylaxis and tachycardia, 
and being independent of β-adrenergic 
receptors conditions, gives a clinical 
advantage to phosphodiesterase III 
ADVERSE EFFECTS OF CATECHOLAMINES ADMINISTRATION
• increase of oxygen consumption 
• arrhythmogenic effect
• tachyphylaxis
• increased risk of sudden cardiac death
• difficulty during β-blockers administration
• dependency about functional condition of β-adrenergic receptors
Table 1. Adverse effects of catecholamines administration.
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inhibitors, when comparing them with 
the catecholamines.
Despite having a different mechanism 
of action, phosphodiesterase III inhibi-
tors, just like catecholamine inotropic 
agents, increase the intracellular level 
of calcium, thereby possibly damaging 
the myofibrils and causing significant 
rhythm disorders.
Numerous adverse effects and an 
increased mortality are the reasons why 
many clinicians are often unsuccess-
ful with the inotropic agents presently 
in use.  New therapeutic agents have 
been developed in the last few years to 
assist the clinician in the stabilization, 
support and treatment of cardiovascu-
lar disease.
One of the newest groups of inotropic 
agents is a group of agents, which 
increase the affinity of myofibrils for 
calcium and are called calcium sensi-
tizers. Calcium sensitizers are the new-
est heterogeneous group of inotropic 
agents. The best known representa-
tives of this group are levosimendan 
and pimobendan. Levosimendan is 
manufactured by the Finnish phar-
maceutical company Orion and was 
first registered in 2000 in Sweden. The 
European Association of Cardiologists 
incorporated it into the 2005 guidelines 
for the treatment of acute heart failure. 
(2) Calcium sensitizers are divided into 
three groups (table 2) depending on 
their mode of interaction with the mus-
cle fiber.
Positive inotropic effects of levosi-
mendan are achieved by its binding to 
troponin C and calcium, thereby sta-
bilizing the tropomyosin molecule and 
prolonging the duration of actin-myosin 
overlap without a change in the net 
concentration of intracellular calcium. 
The vasodilatory effect of levosimendan 
is reached through activation of ATP-
dependent potassium channels. This 
leads to a decrease in both afterload 
and preload, increased coronary blood 
flow and a resultant anti-ischemic 
effect. Levosimendan is therefore cat-
egorized as an anti-ischemic inotropic 
agent. (3) Additionally, the incidence 
CALCIUM SENSITIZERS
Name   Chemical structure  Classification  Description
EMD57033       tiadiazinone                         group III        used in veterinary
                                                                                                            medicine
ORG 30029        carboximidamide              group III?        laboratory 
                                                                                                             Investigation
CGP 48506         benzodiazocine          direct contact          lab. investigation  
                                                                           with actin (group II)
                                                                      or myosine??
MCI-154          piridazinone                      group I                    clinical investigation 
                                                                                                           in Japan
Pimobendan    piridazinone                       group I                    clinical use
Levosimendan      piridazinone                      group II                    clinical use
Table 2. Calcium sensitizers.
Figure 1. Mechanisms of action of calcium sensitizers.
CALCIUM SENSITIZERS
Group III Group I
Group II
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of arrhythmias is extremely low, there 
is no development of tolerance to its 
pharmacological effects, and the simul-
taneous administration of β-blockers 
and calcium channels blockers do not 
produce serious adverse effects. 
Clinical studies conducted on patients 
with acute and chronic heart failure 
treated with β-adrenergic agonists and 
phosphodiesterase III inhibitors have 
given evidence to the limits of their 
use. This is why numerous randomized 
clinical trials investigating the promising 
effects of levosimendan are being con-
ducted. According to available data, of 
all the vasoactive medicaments the only 
vasoactive agent which improves the 
clinical recovery of patients with acute 
heart failure is levosimendan. (4)
Apart from having an acute effect, 
levosimendan achieves a prolonged 
hemodynamic effect due to its two 
metabolites OR-1855 and OR-1896. 
These two metabolites reach an opti-
mal plasma concentration two days 
after being administered and they can 
be effective for 7-9 days after being 
administered via a 24 hour infusion of 
levosimendan.
The “Dose-ranging” study was the first 
double-blind and placebo controlled 
study analyzing the effects of different 
doses of levosimendan and comparing 
them with dobutamine and placebo. 
After being administered for 24 hours 
all doses of levosimendan statistical-
ly had a significant decrease of the 
PCWP in comparison to dobutamine 
and placebo. The infusion of different 
doses of levosimendan 0.4 and 0.6 
μg/kg/min caused a statistically sig-
nificant increase of the cardiac minute 
volume. (5)
The “Dose-escalation” study was con-
ducted on 146 patients with acute heart 
failure and left ventricle systolic dys-
function. Levosimendan was adminis-
tered as a bolus dose of 6μg/kg and 
subsequently as a continuous infusion 
up to a maximum dose of 0.4 μg/kg/
min. Levosimendan had increased the 
stroke volume output and decreased the 
PCWP in comparison to placebo. With a 
favorable hemodynamic effect after a 
6 hour administration levosimendan 
of oxygen in the myocardium remained 
unchanged. (9)
In a randomized placebo controlled and 
fourfold-blind study, the first one ever, 
conducted on patients who underwent 
OPCABG surgery, with normal left ven-
tricle function, the authors have given 
evidence of new therapy options of 
levosimendan. Namely, the administra-
tion of levosimendan at 12μg/kg/min 
through 10 minutes in comparison to 
24μg/kg/min and placebo showed a 
more favorable effect on the systolic 
function of the heart. In conclusion the 
authors recommend levosimendan as 
a new therapy option for the investi-
gated group of patients. (10)
In another double-blind randomized 
and placebo controlled study the dose 
of levosimendan of 12μg/kg through 10 
minutes in comparison with placebo 
administered to patients undergoing 
OPCABG surgery also had a favorable 
hemodynamic effect on the systolic 
function of the left heart. (11)
Somewhat later it was also proven 
that there was a prolonged favorable 
hemodynamic effect of levosimendan 
using two independent methods 
– thermodilution and transesophageal 
ultrasound. (12).
Most of our cells possess endogenous 
showed a good clinical effect signifi-
cantly decreasing dyspnea and fatigue 
in acutely decompensate patients. (6)
In two large randomized studies, RUS-
SLAN and LIDO, it was documented 
that positive hemodynamic effects and 
a lower mortality was seen in patients 
who received levosimendan in com-
parison to patients who received dob-
utamine or placebo. (7,8) Also, there is 
much interest in levosimendan admin-
istration in patients with open-heart sur-
gery, especially in those with off-pump 
procedure. 
Levosimendan was investigated in 
numerous prospective clinical studies 
involving patients undergoing cardiac 
surgery. In the first randomized and 
double-blind study Lileberg et al. inves-
tigated the coronary hemodynamics 
and oxygen consumption in the myo-
cardium after the administration of lev-
osimendan. Patients were divided into 
two groups with respect to the dose of 
levosimendan of 8μg/kg/min or 24μg/
kg/min and placebo. After both doses 
of levosimendan, there was a significant 
rise in the cardiac minute output and a 
decrease in systemic and pulmonary 
vascular resistance. The flow through 
the coronary sinus increased from 28 
to 42 ml meanwhile the consumption 
Figure 2. Preconditioning mechanisms - opening of KATP – channels in the 
sarcolemma and the mitochondria.
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protective mechanisms which if acti-
vated prior to ischemia protect the cell 
from the damage induced by ischemia. 
This protective mechanism is called 
preconditioning and the stimuli along 
with short-term ischemia can be some 
drugs. Murry et al. first described 
ischemic preconditioning in 1986. 
Warltier, two years later describes pre-
conditioning via inhalational anesthet-
ics. Preconditioning mechanisms are 
attained through the opening of KATP 
– channels in the sarcolemma or the 
mitochondria (figure 2). (13)
Experiments have confirmed the role 
of levosimendan as an opener of KATP 
– channels in the mitochondria and 
the sarcolemma of myocites. Tritapepe 
et al. (14) administered an infusion of 
24μg/kg of levosimendan through 10 
minutes directly prior to the applica-
tion of a cardiopulmonary bypass. By 
monitoring the perioperative hemody-
namic parameters and the concen-
tration of cardiac troponin I through a 
period of 48 hours they have proven a 
lower postoperative concentration of 
troponin I (P<0.05) and a higher car-
diac index (P<0.05) in comparison to 
the control group. The group of patients 
that received a short infusion of levosi-
mendan directly prior to CABG had 
shown signs of less damage to the 
myocardium which is indicative of the 
effects of preconditioning.
This result is of great clinical significance 
because a short-term administration of 
levosimendan directly prior to ischemia 
could decrease the intraoperative dam-
age of the myocardium.    
CONCLUSION
Historically, the catecholamines ino-
tropic agents were first line medications 
used in the treatment of cardiovascular 
compromise, but their benefits were 
often overshadowed by major compli-
cations, such as increased mortality. 
The introduction of many newer agents 
in newer classes, such as those which 
produce their effects do not change the 
intracellular calcium values represent 
safer, better choices for treatment. Fur-
thermore, through the preconditioning 
mechanisms, levosimendan may have 
an effect on the process of periopera-
tive protection of the myocardium.
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